BYON3521

News alerts, weekly reports and conference planners

Company:

Byondis

Drug class:

DNA replication inhibitor, c-MET-targeted antibody-drug conjugate

Related drugs:

‹

›

MET expression	Solid Tumor	MET expression	Solid Tumor	BYON3521 Sensitive: C2 – Inclusion Criteria BYON3521 Sensitive : C2	BYON3521 Sensitive: C2 – Inclusion Criteria BYON3521 Sensitive : C2
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	BYON3521 Sensitive: C3 – Early Trials BYON3521 Sensitive : C3	BYON3521 Sensitive: C3 – Early Trials BYON3521 Sensitive : C3

Associations
(2)